uniQure Announces Management and Board Changes
September 22 2016 - 4:18PM
uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today
announced that its Board of Directors has accepted the resignation
of Daniel Soland as chief executive officer (CEO) and an executive
member of the Board, effective immediately. The Board is
pleased to announce that Matthew Kapusta, the Company's chief
financial officer (CFO) since January 2015 who also serves as an
executive member of the Board, has been appointed interim
CEO. In addition, Philip Astley-Sparke, a member of the Board
of Directors and former President of uniQure's US operations, has
been elected unanimously by the Board to serve as its
Chairman.
"My decision to resign as Chief Executive
Officer is due solely to personal family reasons," stated Mr.
Soland, "I regret the abrupt nature of this decision but believe
that it is in the best interests of uniQure, its employees and
shareholders to ensure that the business has the fully committed
leadership it requires. I have continued confidence in the
Company's gene therapy platform, its research and clinical
development programs and its leadership in manufacturing. I
wish everyone associated with the Company tremendous
success."
"We thank Dan for his service to uniQure and
wish him well," stated Philip Astley-Sparke, chairman of the board
of uniQure. "We are fortunate to be able to rely on the
continued leadership of Matt Kapusta as interim CEO. Since
joining the Company nearly two years ago, Matt has been
instrumental in completing our landmark collaboration with
Bristol-Myers Squib, recapitalizing the Company and, more recently,
guiding an ongoing, comprehensive strategic planning process.
The Board looks forward to working closely with Matt and the
leadership team."
"This is an exciting and important time for the
Company as we advance our hemophilia B program into a potential
pivotal trial and more clearly define our focus through the
completion of our strategic planning process," stated Mr.
Kapusta. "I am personally energized and fully committed to
driving success at uniQure and ensuring the execution of our key
objectives."
Mr. Kapusta will continue to serve as CFO and
rely on the support of the company's Global Controller, Christian
Klemt, to advance the daily responsibilities of the finance
team.
"At this time, the Board has elected not to
initiate a search process for a permanent CEO while the Company
focuses on implementing the corporate strategy being finalized with
Matt and the leadership team," stated Mr. Astley-Sparke.
Following Mr. Soland's resignation, the Company's Board of
Directors currently consists of seven members, of whom four are
independent within the meaning of the applicable Nasdaq
rules. As a consequence, the Company is in compliance with
Nasdaq Listing Rule 5605, which requires that at least a majority
of the Board consist of independent directors.
About uniQure uniQure is delivering on
the promise of gene therapy - single treatments with potentially
curative results. We are leveraging our modular and validated
technology platform to rapidly advance a pipeline of proprietary
and partnered gene therapies to treat patients with
liver/metabolic, central nervous system and cardiovascular
diseases. www.uniQure.com
uniQure Forward-Looking Statements This
press release contains forward-looking statements. All statements
other than statements of historical fact are forward-looking
statements, which are often indicated by terms such as
"anticipate," "believe," "could," "estimate," "expect," "goal,"
"intend," "look forward to", "may," "plan," "potential," "predict,"
"project," "should," "will," "would" and similar expressions.
Forward-looking statements are based on management's beliefs and
assumptions and on information available to management only as of
the date of this press release. These forward-looking statements
include, but are not limited to, statements regarding the
development of our gene therapy product candidates, the success of
our collaborations and the risk of cessation, delay or lack of
success of any of our ongoing or planned clinical studies and/or
development of our product candidates. Our actual results could
differ materially from those anticipated in these forward-looking
statements for many reasons, including, without limitation, risks
associated with collaboration arrangements, our and our
collaborators' clinical development activities, regulatory
oversight, product commercialization and intellectual property
claims, as well as the risks, uncertainties and other factors
described under the heading "Risk Factors" in uniQure's 2015 Annual
Report on Form 20-F filed with the Securities and Exchange
Commission on April 4, 2016. Given these risks, uncertainties and
other factors, you should not place undue reliance on these
forward-looking statements, and we assume no obligation to update
these forward-looking statements, even if new information becomes
available in the future.
uniQure Contacts:
Maria E. Cantor Direct: 339-970-7536
Mobile: 617-680-9452 m.cantor@uniQure.com
Eva Mulder Direct: +31 20 240 6103
Mobile: +31 6 52 33 15 79 e.mulder@uniQure.com
PDF Version of Release
http://hugin.info/157414/R/2044006/763199.pdf
uniQure NV (NASDAQ:QURE)
Historical Stock Chart
From Mar 2024 to Apr 2024
uniQure NV (NASDAQ:QURE)
Historical Stock Chart
From Apr 2023 to Apr 2024